Brief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
18/06/2026 14:27
BRIEF-Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027 June 18 (Reuters) - AIM ImmunoTech Inc AIM.A:
AIM IMMUNOTECH - DURIPANC PRIMARY ENDPOINT ANALYSIS TO BEGIN DECEMBER 2026; TOPLINE RESULTS EXPECTED Q1 2027
AIM IMMUNOTECH - DURIPANC SECONDARY ENDPOINT ANALYSIS EXPECTED TO BEGIN JUNE 2027
Source text: ID:nGNX4ZcQ9T
Further company coverage: AIM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential